[1] Siegel, R.L., et al., Colorectal cancer statistics, 2020. CA: a cancer journal for clinicians, 2020. 70(3): 145-164.
[2] Bray, F., et al., Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians, 2018. 68(6): 394-424.
[3] Powell, S.M., et al., APC mutations occur early during colorectal tumorigenesis. Nature, 1992. 359(6392): 235-237.
[4] Walther, A., et al., Genetic prognostic and predictive markers in colorectal cancer. Nature Reviews Cancer, 2009. 9(7): 489-499.
[5] Gorelyshev, A., et al., Second-hit APC mutation in a familial adamantinomatous craniopharyngioma. Neuro-oncology, 2020. 22(6): 889-891.
[6] Fearon, E.R., Molecular genetics of colorectal cancer. Annual Review of Pathology: Mechanisms of Disease, 2011. 6: 479-507.
[7] Chi, et al., Long Non-Coding RNA in the Pathogenesis of Cancers. Cells, 2019. 8(9): 1015.
[8] Kim, J., et al., Long noncoding RNA MALAT1 suppresses breast cancer metastasis. Nature genetics, 2018. 50(12): 1705-1715.
[9] Zhang, G., et al., LncRNA MT1JP functions as a ceRNA in regulating FBXW7 through competitively binding to miR-92a-3p in gastric cancer. Molecular cancer, 2018. 17(1): 1-11.
[10] Loewen, G., et al., Functions of lncRNA HOTAIR in lung cancer. Journal of hematology & oncology, 2014. 7(1): 1-10.
[11] Xu, M., et al., lncRNA SNHG6 regulates EZH2 expression by sponging miR-26a/b and miR-214 in colorectal cancer. Journal of hematology & oncology, 2019. 12(1): 1-17.
[12] Jiang, W., et al., Long non-coding RNAs as a determinant of cancer drug resistance: Towards the overcoming of chemoresistance via modulation of lncRNAs. Drug Resistance Updates, 2020. 50: 100683.
[13] Xu, L., et al., LncRNA SNHG11 facilitates tumor metastasis by interacting with and stabilizing HIF-1α. Oncogene, 2020. 39(46): 7005-7018.
[14] Liang, Z.-x., et al., LncRNA RPPH1 promotes colorectal cancer metastasis by interacting with TUBB3 and by promoting exosomes-mediated macrophage M2 polarization. Cell death & disease, 2019. 10(11): 1-17.
[15] Guo, K., et al., LINC01106 drives colorectal cancer growth and stemness through a positive feedback loop to regulate the Gli family factors. Cell death & disease, 2020. 11(10): 1-15.
[16] Wang, F.-W., et al., APC-activated long noncoding RNA inhibits colorectal carcinoma pathogenesis through reduction of exosome production. The Journal of clinical investigation, 2019. 129(2): 727-743.
[17] Cao, M., J. Zhao, and G. Hu, Genome-wide methods for investigating long noncoding RNAs. Biomedicine & Pharmacotherapy, 2019. 111: 395-401.
[18] Dai, L., et al., Temporal expression and functional analysis of long non-coding RNAs in colorectal cancer initiation. J Cell Mol Med, 2019. 23(6): 4127-4138.
[19] Chen, B., et al., The long noncoding RNA CCAT2 induces chromosomal instability through BOP1-AURKB signaling. Gastroenterology, 2020. 159(6): 2146-2162. e33.
[20] Yu, Y., et al., A novel mechanism of lncRNA and miRNA interaction: CCAT2 regulates miR-145 expression by suppressing its maturation process in colon cancer cells. Molecular Cancer, 2017. 16(1): 1-11.
[21] Zhu, P., et al., LncGata6 maintains stemness of intestinal stem cells and promotes intestinal tumorigenesis. Nature cell biology, 2018. 20(10): 1134-1144.
[22] Aghabozorgi, A.S., et al., Role of adenomatous polyposis coli (APC) gene mutations in the pathogenesis of colorectal cancer; current status and perspectives. Biochimie, 2019. 157: 64-71.
[23] Zhang, L., et al., Selective targeting of mutant adenomatous polyposis coli (APC) in colorectal cancer. Science translational medicine, 2016. 8(361): 361ra140-361ra140.
[24] Zhang, L., et al., Multiple roles of APC and its therapeutic implications in colorectal cancer. JNCI: Journal of the National Cancer Institute, 2017. 109(8).
[25] Fodde, R., et al., The APC gene in colorectal cancer. European Journal of Cancer, 2002. 38(7): 867-871.
[26] Mondaca, S., et al., Specific mutations in APC, but not alterations in DNA damage response, associate with outcomes of patients with metastatic colorectal cancer. Gastroenterology, 2020. 159(5): 1975-1978.
[27] Lesko, A.C., et al., Exploiting APC function as a novel cancer therapy. Curr Drug Targets, 2014. 15(1): 90-102.
[28] Kastritis, E., et al., Somatic mutations of adenomatous polyposis coli gene and nuclear b-catenin accumulation have prognostic significance in invasive urothelial carcinomas: evidence for Wnt pathway implication. Int J Cancer, 2009. 124(1): 103-8.
[29] Abraham, S.C., et al., Genetic and immunohistochemical analysis of pancreatic acinar cell carcinoma: frequent allelic loss on chromosome 11p and alterations in the APC/beta-catenin pathway. Am J Pathol, 2002. 160(3): 953-62.
[30] Ohgaki, H., et al., APC mutations are infrequent but present in human lung cancer. Cancer Lett, 2004. 207(2): 197-203.
[31] Chang, Y.S., et al., Analysing the mutational status of adenomatous polyposis coli (APC) gene in breast cancer. Cancer cell international, 2016. 16(1): 1-6.
[32] Zhang, M., et al., The lncRNA NEAT1 activates Wnt/β-catenin signaling and promotes colorectal cancer progression via interacting with DDX5. Journal of hematology & oncology, 2018. 11(1): 1-13.
[33] Saeinasab, M., et al., SNHG15 is a bifunctional MYC-regulated noncoding locus encoding a lncRNA that promotes cell proliferation, invasion and drug resistance in colorectal cancer by interacting with AIF. Journal of Experimental & Clinical Cancer Research, 2019. 38(1): 1-16.
[34] Jiang, H., et al., Long non-coding RNA SNHG15 interacts with and stabilizes transcription factor Slug and promotes colon cancer progression. Cancer letters, 2018. 425: 78-87.
[35] Huarte, M., et al., The emerging role of lncRNAs in cancer. Nature medicine, 2015. 21(11): 1253-1261.
[36] Tang, J., et al., LncRNA GLCC1 promotes colorectal carcinogenesis and glucose metabolism by stabilizing c-Myc. Nature communications, 2019. 10(1): 1-15.
[37] Han, P., et al., The lncRNA CRNDE promotes colorectal cancer cell proliferation and chemoresistance via miR-181a-5p-mediated regulation of Wnt/β-catenin signaling. Molecular cancer, 2017. 16(1): 1-13.
[38] Niu, Y., et al., miR-185-5p targets ROCK2 and inhibits cell migration and invasion of hepatocellular carcinoma. Oncol Lett, 2019. 17(6): 5087-5093.
[39] Pei, K., et al., MicroRNA-185-5p modulates chemosensitivity of human non-small cell lung cancer to cisplatin via targeting ABCC1. Eur Rev Med Pharmacol Sci, 2016. 20(22): 4697-4704.
[40] Wei, J., et al., MiR-185-5p Protects Against Angiogenesis in Polycystic Ovary Syndrome by Targeting VEGFA. Front Pharmacol, 2020. 11: 1030.
[41] Liu, J.Q., et al., lncRNA KLF3-AS1 Suppresses Cell Migration and Invasion in ESCC by Impairing miR-185-5p-Targeted KLF3 Inhibition. Mol Ther Nucleic Acids, 2020. 20: 231-241.
[42] Ni, W., et al., FoxD2-AS1 promotes glioma progression by regulating miR-185-5P/HMGA2 axis and PI3K/AKT signaling pathway. Aging (Albany NY), 2019. 11(5): 1427-1439.
[43] Zhuang, S.T., et al., LncRNA NEAT1/miR-185-5p/IGF2 axis regulates the invasion and migration of colon cancer. Mol Genet Genomic Med, 2020. 8(4): e1125.